Vertex 3Q Revenues: $221.7 million (-34%) 3Q Loss: $124.1 million (loss of $57.5 million 3Q12) Comments: Incivek revenues were $85.6 million in the quarter, compared to $254.3 million 3Q12, reflecting the continued and rapid decline in the number of people being treated with Incivek as new hepatitis C drug near approval. Kalydeco revenues were $101.1 million, down 105%. Royalty revenues from Invico were $21.0 million, up 5%.   Vertex announced plans to eliminate 370 positions, primarily relat...